Zinman B, et al. - Following the EMPA-REG OUTCOME trial, researchers assessed the relative impacts of empagliflozin in women vs men with type 2 diabetes and cardiovascular (CV) disease. Study participants were people with type 2 diabetes (HbA_1c 53–86 mmol/mol [7–10%] and eGFR >30 ml min^-1 [1.73 m]^-2), with established atherosclerotic CV disease. For this investigation, patients were randomized to receive empagliflozin 10 mg or 25 mg, or placebo once daily in addition to standard of care, and followed. It was observed in the findings that between women and men, CV death, heart failure hospitalization and incident or worsening nephropathy rate reductions due to empagliflozin were not different.